Emphasis on Aggressive Cancer Cells

Oncolytic Viruses

Manufacturing Oncolytic Viruses: Where Complexity Demands Experience

Mathias Kahl

IDT Biologika

MRD

Measurable Residual Disease Moves Deeper Into Hematologic Cancer Development

Pharma's Almanac

BsAbs in Oncology

Bispecific Antibodies Move Into the Heme-Onc Mainstream

David Alvaro, Ph.D.

Pharma's Almanac

Pediatric Oncology

Why Pediatric Oncology Needs Its Own Drug Development Paradigm

David Alvaro, Ph.D.

Pharma's Almanac

Masked Antibody

Expanding the Oncology Therapeutic Window Through Masked Antibody Technology

Sean McCarthy, Ph.D; David Alvaro, Ph.D.

CytomX Therapeutics

Vaccine Development

New Vaccine Technologies Expand the Frontiers of Prevention and Treatment

Cynthia A. Challener, Ph.D.

Pharma's Almanac

Vaccines

Beyond Infectious Disease: Vaccines for Cancer and Chronic Conditions

Pharma's Almanac

LAIs

Seven Biotechs Developing Long-Acting Injectable Drugs

Vedangi Joshi

Nice Insight

In Vivo CAR-T

Five Companies Bringing In Vivo CAR-T Therapy Closer to the Clinic

Emma Gormlie

Nice Insight

Oncology

Harnessing Macrophage Biology to Overcome Tumor Immune Evasion

Roy Maute, Ph.D.; David Alvaro, Ph.D.

Pheast Therapeutics

Rare Cancer CGT

Developing Cell and Gene Therapies for Rare Oncology Applications

David Alvaro, Ph.D.

Pharma's Almanac

Tumor-Agnostic

Moving Beyond Tumor Origin: The Rise of Tissue-Agnostic Oncology

David Alvaro, Ph.D.

Pharma's Almanac